Related Experiment Video For Lung cancer (non-small cell)
Updated: Mar 18, 2026
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection
Beatriz Jimenez-Munarriz1, Berenice Urtecho1, Mary R Rabey1
1Medical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Abstract:
Circulating tumour DNA (ctDNA) offers a minimally invasive approach for early detection of cancer, monitoring molecular residual disease, assessing molecular response and identifying treatment resistance in advanced stages. Additionally, ctDNA enhances clinical decision-making by enabling real-time tumour assessment. This review highlights the growing role of liquid biopsy as a predictive and prognostic tool in non-small cell lung cancer management.
